R&D and commercial alliances in June were wholly dominated by partnerships between big names in molecular diagnostics, such as Johnson & Johnson 's Janssen Biotech Inc., Cepheid and Qiagen NV.
Pacts In Medtech: May/June 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. In this edition, we highlight industry pacts that were sealed in May and June 2017.
More from Business
• By
Abbott presented late-breaking data at the 2025 American College of Cardiology conference demonstrating that TriClip transcatheter edge-to-edge repair offers prolonged patient benefits compared to medical treatment alone after two years, which were not evident at one year.
• By
The Cologuard Plus test has a sensitivity of 95% and a specificity of 94% for the detection of colorectal cancer; “unmatched accuracy,” according to Exact Sciences.
• By
Leann Sims joins AbundaBox as COO; Oura Ring firm appoints CMO.
More from Medtech Insight
• By
In an interview with Medtech Insight, Dexcom’s COO Jake Leach and Adrian Gut, senior director international access, discuss the company’s global expansion, the role of AI in diabetes management, the challenges of securing reimbursement, and how regulators are influencing the future of CGM technology.
• By
Energy and Commerce Health Subcommittee Democrats focus on criticizing HHS Secretary Kennedy’s RIF announcement, including 3,500 FDA jobs among cuts across HHS agencies. Representatives were left wondering if user fee programs would continue, even if reauthorized.
• By
A seemingly humorous social media post on April Fool’s Day struck a nerve with regulatory experts, reflecting real concerns about recent actions by the US Food and Drug Administration.